Economic Evaluation of the PCSK9 Inhibitors in Prevention of the Cardiovascular Diseases

被引：0
|
作者：
Parth Shah
机构：
[1] ObvioHealth,
来源：
Current Cardiology Reports | 2018年 / 20卷
关键词：
Alirocumab; Evolocumab; PCSK9; Cardiovascular; Cholesterol; Lipoprotein (a);
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Current and future role of PCSK9 inhibitors in ASCVD prevention
    Greco, Antonio
    Capodanno, Davide
    FUTURE CARDIOLOGY, 2025, 21 (02) : 71 - 73
  • [42] Oral PCSK9 Inhibitors
    Agarwala, Anandita
    Asim, Ramsha
    Ballantyne, Christie M.
    CURRENT ATHEROSCLEROSIS REPORTS, 2024, 26 (05) : 147 - 152
  • [43] PCSK9 inhibitors are go
    Asher Mullard
    Nature Reviews Drug Discovery, 2015, 14 : 593 - 593
  • [44] PCSK9 in metabolism and diseases
    Ajoolabady, Amir
    Pratico, Domenico
    Mazidi, Mohsen
    Davies, Ian G.
    Lip, Gregory Y. H.
    Seidah, Nabil
    Libby, Peter
    Kroemer, Guido
    Ren, Jun
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2025, 163
  • [45] PCSK9 inhibitors and cardiovascular disease: heralding a new therapeutic era
    Chapman, M. John
    Stock, Jane K.
    Ginsberg, Henry N.
    CURRENT OPINION IN LIPIDOLOGY, 2015, 26 (06) : 511 - 520
  • [46] The pleiotropic effects of PCSK9 in cardiovascular diseases beyond cholesterol metabolism
    Liu, Gang
    Yu, Xiatian
    Cui, Chaochu
    Li, Xiao
    Wang, Tianyun
    Palade, Philip T.
    Mehta, Jawahar L.
    Wang, Xianwei
    ACTA PHYSIOLOGICA, 2025, 241 (02)
  • [47] PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease
    Schmidt, Amand F.
    Pearce, Lucy S.
    Wilkins, John T.
    Overington, John P.
    Hingorani, Aroon D.
    Casas, Juan P.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2017, (04):
  • [48] PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease
    Schmidt, Amand F.
    Carter, John-Paul L.
    Pearce, Lucy S.
    Wilkins, John T.
    Overington, John P.
    Hingorani, Aroon D.
    Casas, J. P.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2020, (10):
  • [49] PCSK9 Inhibitors in Secondary Prevention-An Opportunity for Personalized Therapy
    Board, Chase
    Kelly, Michael S.
    Shapiro, Michael D.
    Dixon, Dave L.
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2020, 75 (05) : 410 - 420
  • [50] Pleiotropic Effects of PCSK9 Inhibitors on Cardio-Cerebrovascular Diseases
    Li, Zhenzhen
    Zhu, Lin
    Xu, Yeqiong
    Zhang, Yiting
    Liu, Yukai
    Sun, Huiling
    Li, Shuo
    Wang, Meng
    Jiang, Teng
    Zhou, Junshan
    Deng, Qiwen
    BIOMEDICINES, 2024, 12 (12)
12345